Arakeeb, A., Abu- Zaid, M., Elwan, N., Elsharaby, R. (2023). Role of Soluble Programmed Cell Death- 1 in Rheumatoid Arthritis Patients. The Egyptian Journal of Hospital Medicine, 90(2), 3112-3118. doi: 10.21608/ejhm.2023.288404
Asmaa Ragab Arakeeb; Mohammed Hassan Abu- Zaid; Nahed Mohamed Elwan; Radwa Mahmoud Elsharaby. "Role of Soluble Programmed Cell Death- 1 in Rheumatoid Arthritis Patients". The Egyptian Journal of Hospital Medicine, 90, 2, 2023, 3112-3118. doi: 10.21608/ejhm.2023.288404
Arakeeb, A., Abu- Zaid, M., Elwan, N., Elsharaby, R. (2023). 'Role of Soluble Programmed Cell Death- 1 in Rheumatoid Arthritis Patients', The Egyptian Journal of Hospital Medicine, 90(2), pp. 3112-3118. doi: 10.21608/ejhm.2023.288404
Arakeeb, A., Abu- Zaid, M., Elwan, N., Elsharaby, R. Role of Soluble Programmed Cell Death- 1 in Rheumatoid Arthritis Patients. The Egyptian Journal of Hospital Medicine, 2023; 90(2): 3112-3118. doi: 10.21608/ejhm.2023.288404
Role of Soluble Programmed Cell Death- 1 in Rheumatoid Arthritis Patients
Background: A transmembrane glycoprotein called soluble programmed death-1 (sPD-1) is expressed on T cells and is secreted into synovial fluid and peripheral circulation by proteolytic cleavage of membrane-bound protein. Objectives: Assessment of sPD-1 plasma levels in cases with rheumatoid arthritis (RA) and the link with disease activity, laboratory, and clinical parameters. Methods: This research involved 20 active RA cases with DAS score (> 2.6 score), 20 patients in remission (≤ 2.6 score), and 20 apparently healthy individuals as control group. All studied groups were subjected to obtaining patient histories, doing clinical assessments, and performing laboratory tests in form of CBC, ESR, CRP, RF, and Ant-CCP. Measurements of sPD-1 plasma levels and correlations with clinical, laboratory, and disease activities were made. Results: Regarding demographic information, there were no notable differences across RA patients and controls (P > 0.05). In comparing DAS score of the studied groups, there was a significant increase in active group than remission group. There was a significant increase of SPD-1 levels in active group compared to remission and control groups (P = 0.001), while it was not significant regarding remission and control groups (P=0.054). Positive associations were found between the sPDL-1 and the ESR, Anti-CCP, CRP, and DAS score. Conclusion: Plasma sPD-1 in RA cases was significantly raised, and they correlate with DAS28, demonstrating that sPD-1 could be a useful indicator of the degree of RA disease activity. SPD-1 might be a new biomarker or target for RA immunomodulatory treatment.